In this exclusive interview, Midden -Soste Health speaks with Nurgl Vatasever, Vice -President Eemea, Beckman Coulter, about the latest diagnostic innovations and strategic direction of the company. With systems that test more than a million samples every hour, Beckman Coulter continues to promote laboratory medicine through analyzers with high transit such as the DXI 9000 and automation solutions. Vatasever describes how these technologies deal with critical challenges in health care, from limitations of staff to the growing diagnostic demand, while sharing insights into emerging biomarkers and the joint approach to the healthcare strength through regions.
Health in the Middle East: Beckman Coulter has a global-national legacy in the diagnostic industry. How would you characterize the current position of the company in the global diagnostic industry, and what unique value does it bring for healthcare systems in Eemea regions?
Koek Vatasever: Every hour all over the world, more than a million samples are tested on Beckman Coulter Diagnostic Systems, which even influence 1.2 billion patients and more than three million clinic for years. Through our innovative diagnostic solutions we are aimed at processing clinical laboratories in Eemea offers accurate diagnostic information to clinicians and patients who make high quality care possible.
What distinguishes us is how help healthcare systems tackle real challenges, such as limited resources, employee restrictions and growing demand. Our scalable portfolio – in Imunassay, Chemistry, Hematology, Microbiology and Urinesia – helps laboratories to do more with less.
By automating important laboratories, we reduce the workload and improve rapid and reliable sample analysis results. That means that clinicians get the fear they need faster, and patients can start treatment sooner. It’s all about making better results possible with more efficient.
Meh: The launch of the DXI9000 Immunassay Analyzer is an important progress in diagnostic technology. Could you comment on how the technical possibilities – in particular the transit capacity and reduced sample volume requirements – transform clinical laboratory workflows and patient care?
Koek Vatasever: The launch of the DXI 9000 Immunassay Analyzer really marks a new chapter in diagnostic innovation. The high-throughput capacity and high sensitivity Immunasay test options for the core laboratories are striking functions-with which laboratories process a significantly larger volume of samples with speed and precision. The ability to streamline workflows and reduce Turaround Times is a game changer for laboratories that manage high workload under Resource restrictions.
Middle East Health: Healthcare Systems are confronted with the increasing pressure to deliver more precise diagnostics with fewer resources. How does the DXC 500I Clinical Analyzer take on these challenges and what improvements in clinical decision -making have you included from its implementation?
Koek Vatasever: The DXC 500I Clinical Analyzer is designed to bring automation to the low transit space, in particular for integrated health networks with several more smaller laboratories. The DXC 500I combines advanced technology with an intuitive user interface, allowing that laboratory of all species to meet the growing requirements of modern health care. With thisput of a maximum of 800 clinical chemistry tests per hour and 100 immunassay tests per hour, this analyzer yields precise and reliable results for timely clinical decision-making. The challenge is to reduce precise diagnostics with fewer sources by streamlining workflows and reducing the need for manual intervention. This changes more consistent, reliable results and ultimately helps Labs to work more efficiently without endangering diagnostic quality.
Health of the Middle East: What emerging biomarkers or diagnostic paramers is your R&D pipeline export ring that could transform the early description in the next 3-5 years?
Koek Vatasever: We are enthusiastic about our pipeline of diagnostic assays to tackle a wide range of diseases. For example, the DXI 9000 analyzer has shown that the ability to develop the sensitive and clinically reserved Assysys. With the help of this possibility we develop into blood -based Alzheimer’s Disease test. Recently the US Food and Drug Administration (FDA) indicated break-through equipment to Beckman Coulter’s running access P-TAU217/-Amyloid 1-42 Plasmavatio. This blood test is designated to help healthcare providers identify patients with amyloid pathology associated with Alzheimer’s disease.
Health in the Middle East: What collaborative initiatives did Beckman Coulter develop with care providers to strengthen diagnostic precision and scalability?
Koek Vatasever: At Beckman Coulter Diagnostics we place great value on partnerships with all levels of stakeholders, including healthcare, channel partners and institutions professionals. We work closely with these partners to identify Amet needs, to create tailor -made solutions, to enter into this thought leadership program and to stimulate continuous innovation. This approach helps us to anticipate the future of diagnostics, optimize professional education and integrate advanced technologies to improve patient care.
Health in the Middle East: Educational partnerships Offen accelerate the acceptance of advanced diagnostic platforms. What specific educational projects did your team implement to manage healthcare providers, can maximize the clinical use of your technologies?
Koek Vatasever: Education is a cornerstone of our strategy to support the approval of advanced diagnostics. One of our most important initiatives is the Beckman Coulter Dubai Vision Center – a special learning facility that offers certified service and application training, tailor -made customer programs and scientific lectures. We offer interactive tutorials, hands-on workshops and understanding materials, all adapted to meet the specific needs of laboratories in the EEMEA region.
Through these educational partnerships we are fully equipped from health care professionals to maximize the clinical use of our technologies.
Health in the Middle East: Your career -Trarbery has led you to this crucial leadership role. What forming experiences have your subscription of the challenges of the diagnostic sector, and how do these insights inform your strategic direction for the EEMEA region?
Koek Vatasever: Starting my career as the first female engineer at Hitachi Medical Systems in Turkiye, I had the opportunity to work in different regions -including Russia, Eastern Europe, the Middle East and Africa. The experiences have given me a broad perspective on the unique challenges and opportunities of the health care sector. They formed my endorsement of critical issues such as unequal access to diagnostics, infrastructure and employee restrictions.
They also strengthened the importance of scalable, local release solutions and the power of strong partnerships. At Beckman Coulter Diagnostics, before Insights guides my strategic direction for the Eemea region that cooperates with our customers to increase the access to high quality diagnostics, intentions in education and service, and to work closely with stakeholders at Stregthen Healthcare Systems and patient care.
Health in the Middle East: Can you tell us something about your leadership style? What is your method for building a productive workplace culture and effective employees involved?
Koek Vatasever: My leadership style is aimed at cooperation, empowerment and data -driven decisions, with a strong emphasis on compassionate leadership. I strive to create a converonation in which team members feel appreciated, familiar and motivated to take their work owner. Open communication, empathy and continuous improvement are the key to promoting success together.
To build a productive workplace culture and effective concept of employee, I concentrate on accuracy, respect and celebrating both team performance and team performance. I prioritize that I am concerned with my team and to make sure that everyone feels supported and authorized to grow in their role. By promoting psychological safety and finding an open-door mentality and finding team members to express ideas freely, fear of judgment. This, combined with clear expectations and continuous feedback, builds a basis of trust in the capacity of the team to innovate and at best strengthens.
About the Vatasever of Nurgül
Nurgül Vatasever is the Eemea Vice President at Beckman Coulter. In addition to stimulating commercial priorities, she is committed to promoting powerful culture by offering strategic leadership, coaching and talent development throughout the region.
With extensive experience in health care, Nurgül has managed various markets in the middle, Africa, Turkey, Russia, CIS -Landen and Midden -Oost -Europa. She has kept senior leadership roles of increasing responsibility in salales, service, marketing and general management at Medtronic, Johnson & Johnson, GE Healthcare and Hitachi Medical Systems.
During her 25-year career in medical devices and health care, she was collected for her dedication to ethical leadership, the cultivation of a winning culture and prioritizing talent through attraction, developing and maintaining well-performing, diverse teams.
